title: Can curative antivirals benefit porphyria cutanea tarda in hepatitis C patients?
authors.affiliation: Texas Tech University Health Sciences Center, Lubbock, TX, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Hatch
authors.affiliation: Center for Clinical Studies, Houston, TX, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Nawas
authors.affiliation: Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
authors.forename: R
authors.initials: R
authors.lastname: Kollipara
authors.affiliation: Department of Dermatology, The University of Texas Health Sciences Center at Houston, Houston, TX, USA.
authors.forename: S K
authors.initials: SK
authors.lastname: Tyring
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017119:Porphyria Cutanea Tarda / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents